1. Home
  2. SAGE vs AMCX Comparison

SAGE vs AMCX Comparison

Compare SAGE & AMCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAGE
  • AMCX
  • Stock Information
  • Founded
  • SAGE 2010
  • AMCX 1980
  • Country
  • SAGE United States
  • AMCX United States
  • Employees
  • SAGE N/A
  • AMCX N/A
  • Industry
  • SAGE Biotechnology: Pharmaceutical Preparations
  • AMCX Cable & Other Pay Television Services
  • Sector
  • SAGE Health Care
  • AMCX Telecommunications
  • Exchange
  • SAGE Nasdaq
  • AMCX Nasdaq
  • Market Cap
  • SAGE 462.2M
  • AMCX 436.4M
  • IPO Year
  • SAGE 2014
  • AMCX 2011
  • Fundamental
  • Price
  • SAGE $6.94
  • AMCX $8.99
  • Analyst Decision
  • SAGE Hold
  • AMCX Hold
  • Analyst Count
  • SAGE 20
  • AMCX 3
  • Target Price
  • SAGE $11.39
  • AMCX $9.33
  • AVG Volume (30 Days)
  • SAGE 2.8M
  • AMCX 459.6K
  • Earning Date
  • SAGE 02-12-2025
  • AMCX 02-07-2025
  • Dividend Yield
  • SAGE N/A
  • AMCX N/A
  • EPS Growth
  • SAGE N/A
  • AMCX N/A
  • EPS
  • SAGE N/A
  • AMCX 0.79
  • Revenue
  • SAGE $106,399,000.00
  • AMCX $2,500,857,000.00
  • Revenue This Year
  • SAGE N/A
  • AMCX N/A
  • Revenue Next Year
  • SAGE $122.32
  • AMCX N/A
  • P/E Ratio
  • SAGE N/A
  • AMCX $11.41
  • Revenue Growth
  • SAGE 837.60
  • AMCX N/A
  • 52 Week Low
  • SAGE $4.62
  • AMCX $7.08
  • 52 Week High
  • SAGE $27.68
  • AMCX $19.39
  • Technical
  • Relative Strength Index (RSI)
  • SAGE 60.28
  • AMCX 45.28
  • Support Level
  • SAGE $6.75
  • AMCX $8.82
  • Resistance Level
  • SAGE $7.88
  • AMCX $9.20
  • Average True Range (ATR)
  • SAGE 0.38
  • AMCX 0.39
  • MACD
  • SAGE 0.13
  • AMCX -0.08
  • Stochastic Oscillator
  • SAGE 64.39
  • AMCX 37.04

About SAGE Sage Therapeutics Inc.

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

About AMCX AMC Networks Inc.

AMC Networks owns several linear pay-TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network, reached nearly 65 million pay-TV households in the US at the end of 2023. The firm also had nearly 11.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.

Share on Social Networks: